A nurse is caring for a client who has a prescription for ceftriaxone. The nurse should monitor the client for which of the following adverse effects?

B. Maculopapular rash is a potential adverse effect of ceftriaxone. It is a type of skin rash characterized by flat, red areas (macules) and raised, bumpy areas (papules). If a client develops a rash while taking ceftriaxone, it should be reported to the healthcare provider for evaluation.

A. Constipation is not a common adverse effect of ceftriaxone. It is more commonly associated with other medications or medical conditions unrelated to ceftriaxone.
C. Pitting edema is not a common adverse effect of ceftriaxone. It may occur as a result of other medical conditions or medications, but it is not specifically associated with ceftriaxone.
D. Concentrated urine is not a common adverse effect of ceftriaxone.

D. The Quadrivalent human papillomavirus (HPV) vaccine is recommended for both males and females to protect against certain strains of HPV that can lead to cervical cancer, genital warts, and other HPV- related cancers. It is typically administered in a series of doses starting around 11-12 years of age.
A. Hepatitis B vaccine is typically administered at birth, followed by a series of doses at 1-2 months and 6-18 months of age. By the age of 11, the child would have completed the series if they were up to date on immunizations. Therefore, it is unlikely that the child would need another dose of the Hepatitis B vaccine at this age.
B. Rotavirus vaccine is usually administered in infancy, with the first dose given around 2 months of age and the last dose by 8 months of age. By the age of 11, the child would have completed the series if they were up to date on immunizations. So, administering the Rotavirus vaccine to an 11-year-old who is up to date on immunizations is unnecessary.
C. The Pneumococcal conjugate vaccine protects against infections caused by the bacterium Streptococcus pneumoniae, such as pneumonia and meningitis. It is typically administered in infancy, with a booster dose recommended at around 12-15 months of age. However, the CDC recommends a single revaccination dose of Pneumococcal conjugate vaccine for children aged 6 through 18 years who are at high risk of infection. If the child falls into this category, the nurse should plan to administer the vaccine.